Financing ·
China SXT Pharmaceuticals announces $12M registered direct offering of shares at $1.50
SXTCChina SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals announced a definitive agreement with institutional investors for a registered direct offering of up to 8,000,000 Class A ordinary shares (or pre-funded warrants) at $1.50 per share, generating approximately $12 million in gross proceeds. The company will also issue 8,000,000 common warrants exercisable at $2.75 per share for a one-year term. Investors hold an additional purchase right to acquire up to another $12 million of securities within 30 days after closing. The offering is expected to close on or about October 9, 2026, subject to customary conditions. China SXT Pharmaceuticals Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.